The U.S. and China Are Talking Again. What Actually Changed?

In September, presidents Donald Trump and Xi Jinping met at the White House amid ceremonial pageantry and the familiar list of hard questions: tariffs, chips, rare-earth minerals, Taiwan and artificial intelligence. The clearest result was not a sweeping settlement. It was more time.

The two governments extended a fragile trade truce, first reached after tariffs had surged in 2025, until January 10, 2027, according to U.S. Treasury Secretary Scott Bessent. He said negotiators wanted time to explore a bigger agreement. Reuters reported no major breakthrough at the summit, and noted that the White House had not issued its own detailed readout of the leaders’ private exchange.[1] [2]

That is what “talking again” means in practice: top-level contact has become regular, and officials have reopened channels to manage disputes. But the talks have not erased the tariffs, export controls, or strategic mistrust that made the relationship dangerous in the first place.

From tariff shock to a pause with an expiry date

The current process began as crisis management. In April 2025, the United States and China escalated tariffs and retaliatory measures. At Geneva the following month, they agreed to suspend 24 percentage points of their additional tariffs for an initial 90 days, while retaining a 10-point rate, and to remove other recent tariff increases. China also agreed to suspend or remove non-tariff countermeasures imposed since April 2. The joint statement established a mechanism for further discussions; it did not settle the wider trade relationship.[3]

That distinction matters. A pause is not the same as cancellation. The Geneva statement set a clock and a negotiating mechanism, not a final bargain over market access, industrial policy or technology restrictions.

After later rounds, a November 2025 package broadened the agenda. The White House said China would pause new rare-earth restrictions, issue general export licenses for several critical minerals, resume purchases of American farm goods and take steps on fentanyl precursor chemicals. The United States, in turn, said it would reduce a fentanyl-related tariff by 10 percentage points and suspend heightened reciprocal tariffs until November 10, 2026.[4] [5]

The details were not just diplomatic language: a U.S. executive order put the tariff suspension into effect, and specified its end date. But the terms remained temporary. In September 2026, Bessent said the arrangement had been extended another two months, to January 10, 2027. That date is a public statement by the U.S. Treasury secretary, reported by Reuters—not, at the time of publication, a new jointly published treaty or a full public implementation document.[1] [6]

More machinery, but no settled bargain

The May 2026 Trump–Xi meeting in Beijing produced a more institutional ambition. The White House said the presidents had chartered a U.S.–China Board of Trade to manage trade in non-sensitive goods and a Board of Investment to discuss investment issues. It also announced Chinese commitments on agricultural purchases, rare-earth supply concerns and an initial order of 200 Boeing aircraft.[7]

Those are administration announcements, not proof that every commitment has been completed. The point of the boards, if they become operational, is to create a standing place to negotiate instead of treating each dispute as a leader-to-leader emergency. The investment forum could help surface specific obstacles; the trade board could separate lower-risk commerce from sensitive areas. But the public description leaves key questions open: what counts as “non-sensitive,” who participates, and what happens when one side believes the other has not delivered?

By September, both governments had reason to keep that process alive. Bessent said Beijing was meeting its 25-million-ton soybean commitment but lagging on a pledge to buy $17 billion in other agricultural goods, and U.S. officials said rare-earth deliveries were also behind. He floated possible announcements on tariff reductions for $30 billion in non-sensitive goods, financial services and agricultural purchases. These were negotiating possibilities, not concluded terms.[1]

That gap between announced promise and verified delivery is central. In November 2025, the White House described rare-earth general licenses as the “de facto removal” of controls and listed broad commitments. China, however, has described its export controls as lawful national-security measures, not export bans, and says eligible applications can be licensed. Neither side’s characterization alone tells a buyer how quickly a particular shipment will clear.[4] [8]

The chokepoints remain real

The dispute is not simply about tariffs. China’s leverage includes its dominant position in processing some critical minerals used across industries. The United States has leverage through access to advanced chips, manufacturing equipment and other technologies. Both governments have shown a willingness to use restrictions as bargaining tools.

The November package temporarily eased some pressure. China pledged to suspend an expansive new round of rare-earth controls, while Washington paused a rule that would have widened export restrictions to subsidiaries of listed companies. Such reciprocal pauses can prevent immediate supply shocks, but they do not settle the underlying security claims or reverse existing controls.[4] [5]

Technology is where even the new dialogue looks thin. Before the September summit, Bessent said officials had agreed to create a hotline for notifying each other about AI safety incidents. Reuters reported that China’s public response did not confirm the hotline agreement, and that analysts saw little basis for substantial cooperation while both countries were competing to lead AI development.[1] A communications channel, if it functions, can help manage an incident; it is not a shared AI rulebook.

Fentanyl shows how a politically urgent issue can remain contested even while officials negotiate. In March 2026, U.S. and Chinese representatives publicly clashed at a United Nations drugs meeting. Washington accused Beijing of failing to stop precursor sales; China rejected the allegation and criticized the use of tariffs. Reuters reported that the U.S. Supreme Court had invalidated a 10% fentanyl-related tariff imposed under an emergency statute. That ruling changed the legal basis for one tariff, not the two governments’ disagreement over enforcement or responsibility.[9]

Taiwan is not a side issue

Trade can be paused and restarted by executive action. Taiwan is a more consequential strategic fault line. After the September meeting, China’s official news agency reported that Xi urged the United States to oppose Taiwan independence. Reuters noted that the White House had not provided its own readout of that exchange and reported no sign Washington had changed its long-standing formulation that it does not support independence.[2]

This is an example of why competing readouts matter. Beijing’s account states its position; it does not establish that Washington accepted it. Nor does a summit photo establish that the two sides have narrowed their disagreement. Any shift in U.S. wording or arms policy would have implications for Taiwan and U.S. allies, but the publicly available record at publication does not show that such a shift was agreed at this meeting.[2]